Outset Medical (OM) Set to Post Quarterly Earnings on Wednesday

Outset Medical (NASDAQ:OM) is expected to issue its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to post earnings of ($0.64) per share and revenue of $31.40 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Outset Medical (NASDAQ:OM) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.08). The company had revenue of $31.64 million during the quarter, compared to analysts’ expectations of $28.97 million. On average, analysts expect Outset Medical to post ($3.81) EPS for the current fiscal year and ($3.01) EPS for the next fiscal year.

Outset Medical Stock Performance

OM traded down $0.10 during trading on Wednesday, hitting $4.24. The stock had a trading volume of 2,928 shares, compared to its average volume of 345,638. The company’s 50-day moving average price is $3.73 and its 200 day moving average price is $4.17. Outset Medical has a twelve month low of $2.84 and a twelve month high of $14.25.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on OM shares. Wall Street Zen raised shares of Outset Medical from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Weiss Ratings cut shares of Outset Medical from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 21st. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Outset Medical has a consensus rating of “Hold” and an average price target of $10.00.

Outset Medical Company Profile

Outset Medical, Inc is a medical technology company that develops products for hemodialysis, a treatment that filters waste and excess fluid from the blood when the kidneys are no longer able to do so adequately. The company’s primary product is the Tablo Hemodialysis System, an integrated dialysis platform designed to simplify treatment for healthcare providers and support broader use of dialysis in hospitals, outpatient facilities and the home.

The Tablo system combines dialysis delivery, water purification and dialysate production in a single device and uses a touchscreen interface intended to guide users through treatment setup and operation.